COUNTERPOINT: No, Biotech Isn't In A Bubble
This article was originally published in Scrip
Talk of a biotech bubble has been rampant since US Federal Reserve Chair Janet Yellen made comments last year about valuations in the industry. The argument that the biotech sector is currently in a bubble is an easy one to make – valuations have been high, the IPO window has been wide open and news of M&A has been in the headlines constantly. Now, more than two years into these plentiful times for biotech, many are wondering if the bubble will burst.